Melanoma
📧 Sign up to get email alerts when something new happens for Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: Study of GV20-0251 in Participants With Solid Tumor Malignancies [Phase 1, Phase 2]
GV20 Therapeutics is evaluating GV20-0251 in a Phase 1/2 trial for adults with various solid tumors, and the study is currently recruiting. …
-
CLINICAL_TRIALS trial_result · 2025-12-03Clinical Trial Update: Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study [Phase 1]
A Phase 1 study evaluating intra-lymphatic STI-3031 delivered with the Sofusa DoseConnect device for in-transit melanoma (clinical stage III…
-
CLINICAL_TRIALS trial_result · 2025-12-03Clinical Trial Update: A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer [Phase 1]
Phase 1 clinical trial evaluating MQ710 with and without pembrolizumab in solid tumors; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: Risk Stratification Among Individuals Who Have Many Moles on Their Skin
Clinical trial update on risk stratification among individuals with many moles (high-risk nevus phenotype). The goal is to better assess mel…
-
CLINICAL_TRIALS trial_result · 2025-11-28Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers [Phase 1, Phase 2]
Phase 1/2 study evaluating the safety and preliminary efficacy of CyPep-1 in combination with pembrolizumab for advanced or metastatic cance…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-11-28Clinical Trial Update: Study of ACC-1898 in Adult Participants With Advanced Solid Tumors [Phase 1]
Phase 1 study update for ACC-1898 in adults with advanced solid tumors; the trial is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2025-11-26Clinical Trial Update: BO-112 With Pembrolizumab in Unresectable Malignant Melanoma [Phase 2]
Phase 2 trial of BO-112 in combination with pembrolizumab for unresectable malignant melanoma has completed, with results posted.
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
This clinical trial update outlines a head-to-head comparison of Opdualag versus Cemiplimab/Fianlimab in patients with unresectable or metas…
-
CLINICAL_TRIALS other · 2025-11-26Clinical Trial Update: Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies [NA]
Clinical trial update for Miltenyi Biomedicine's cell and gene therapy program indicates ongoing recruitment and planned long-term follow-up…
-
CLINICAL_TRIALS trial_result · 2025-11-25Clinical Trial Update: Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers [Phase 1]
Phase 1 clinical trial evaluating hypofractionated radiotherapy in combination with durvalumab (MEDI4736) and tremelimumab in patients with …
-
CLINICAL_TRIALS trial_result · 2025-11-24Clinical Trial Update: Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma [Phase 2]
Phase 2 trial of pembrolizumab plus lenvatinib for brain metastases from melanoma or renal cell carcinoma has been terminated; the update no…
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. [Phase 2, Phase 3]
This clinical trial update describes Arm 03 of the DETERMINE trial evaluating entrectinib in adults, pediatric, and teenage/young adult pati…
-
CLINICAL_TRIALS trial_result · 2025-11-24Clinical Trial Update: DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition [Phase 2, Phase 3]
The update notes ongoing recruitment for the DETERMINE trial Arm 02 investigating atezolizumab in adults and pediatric/young adult patients …
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis
This clinical trial update describes a flow cytometry-based neutrophil biomarker test intended to predict clinical benefit from immunotherap…
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: A Study of GV20-0251 in Advanced or Refractory Solid Tumors [Phase 1]
This Phase 1 clinical trial update indicates that GV20-0251 is being studied in advanced or refractory solid tumors and is currently recruit…
-
CLINICAL_TRIALS trial_result · 2025-11-24Clinical Trial Update: DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. [Phase 2, Phase 3]
Phase 2/3 DETERMINE trial treatment arm 05 is evaluating the combination of vemurafenib and cobimetinib in adults with BRAF-positive cancers…
-
EMA approval · 2025-11-21EMA Authorised: Yervoy (Ipilimumab) — Bristol-Myers Squibb Pharma EEIG
The European Medicines Agency authorised Yervoy (ipilimumab) for multiple cancer indications. It lists melanoma, renal cell carcinoma, non-s…
-
CLINICAL_TRIALS trial_result · 2025-11-21Clinical Trial Update: A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors [Phase 1]
Phase 1 study evaluating CFT1946 as monotherapy and in combination for BRAF V600-mutant solid tumors to assess safety, tolerability, and pre…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors [Phase 1]
This is a Phase 1 clinical trial update for HiFiBiO's HFB200301 as a single agent and in combination with tislelizumab in adults with advanc…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors [Phase 1]
Phase 1 study of HFB200603 as a single agent and in combination with tislelizumab in adults with advanced solid tumors, including renal cell…
-
CLINICAL_TRIALS trial_result · 2025-11-21Clinical Trial Update: APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma [Phase 1, Phase 2]
A Phase 1/2 study evaluating APX005M in combination with pembrolizumab for metastatic melanoma has been terminated, with results posted.
-
CLINICAL_TRIALS withdrawal · 2025-11-21Clinical Trial Update: A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 trial evaluating BT-001 alone and in combination with pembrolizumab in metastatic or advanced solid tumors has been terminated.
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors. [Phase 2]
Phase II clinical trial evaluating multimodal ablation with systemic drug therapy for advanced solid tumors, currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma [Phase 1]
This clinical trial update describes a Phase 1 study of Adze1.C in participants with metastatic melanoma, which is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma [Phase 2]
Phase 2 trial of intratumoral LTX-315 in combination with pembrolizumab for advanced melanoma has completed.